Onyekwere Charles Asabamaka, Odiagah Joan Nwabuaku, Igetei Rufina, Emanuel Amancia Olufunmilayo Duro, Ekere Francis, Smith Stella
Charles Asabamaka Onyekwere, Joan Nwabuaku Odiagah, Rufina Igetei, Amancia Olufunmilayo Duro Emanuel, Francis Ekere, Gastroenterology unit, Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos 999062, Nigeria.
World J Gastroenterol. 2014 Apr 7;20(13):3615-9. doi: 10.3748/wjg.v20.i13.3615.
To investigate the efficacy of a standard triple therapy (comprising rabeprazole, clarithromycin, and amoxicillin) for Helicobacter pylori (H. pylori) eradication, noting factors that influence the outcome and documenting any adverse events.
Following institutional ethical approval, fifty consecutive and consenting symptomatic patients with evidence of H. pylori infection by either a positive urea breath test (UBT) and/or a campylobacter-like organism test who presented to the Gastroenterology clinic of Lagos State University Teaching Hospital between 2012 and 2013 were recruited into the study. Patients were openly randomized to either a 7-d or a 10-d regimen of amoxicillin 1 g, clarithromycin 500 mg and rabeprazole 20 mg twice daily. The extent of symptom resolution was noted following the treatment, and at the end of one month after the completion of treatment, a repeat UBT was performed in each patient to document the eradication of the infection. All data (demographics, symptoms, and eradication rates) were collated and analyzed with SPSS version 18.
Forty-seven patients completed the study (three were excluded from the analysis for breaching the study protocol). The patients included 18 males and 29 females within the age range of 13-80 years (mean 43.7, SD 16.8). The clinical features of the study subjects were dyspepsia, reflux symptoms and features of gastrointestinal bleeding. The average eradication rate was 87.2%. Eighteen subjects were enrolled in the 7-d arm, while 29 were in the 10-d arm. There was no statistically significant difference in the age or sex distributions of the two arms. There was no significant advantage of the 10-d treatment duration over the 7-d duration (P = 0.78), and the eradication outcomes were not influenced by the gender or age of the subjects. No adverse effects were reported in either arm.
The triple therapy regime, employing a combination of amoxicillin, clarithromycin and rabeprazole, showed great efficacy and safety in the eradication of H. pylori, and this outcome was not influenced by gender or age. No difference was observed between the 7-d and 10-d regimens.
研究标准三联疗法（包含雷贝拉唑、克拉霉素和阿莫西林）根除幽门螺杆菌（H. pylori）的疗效，记录影响治疗结果的因素并记录任何不良事件。
经机构伦理批准后，2012年至2013年间连续50例有症状且经尿素呼气试验（UBT）阳性和/或弯曲杆菌样微生物检测证实有幽门螺杆菌感染的患者，自愿到拉各斯州立大学教学医院胃肠病科就诊，被纳入本研究。患者被随机分为两组，一组接受为期7天的治疗方案，另一组接受为期10天的治疗方案，均为阿莫西林1克、克拉霉素500毫克和雷贝拉唑20毫克，每日两次。治疗后记录症状缓解程度，治疗结束后1个月时，对每位患者进行重复尿素呼气试验，以记录感染是否被根除。所有数据（人口统计学、症状和根除率）均采用SPSS 18版进行整理和分析。
47例患者完成了研究（3例因违反研究方案被排除在分析之外）。患者包括18名男性和29名女性，年龄在13 - 80岁之间（平均43.7岁，标准差16.8）。研究对象的临床特征为消化不良、反流症状和胃肠道出血症状。平均根除率为87.2%。18名受试者被纳入7天治疗组，29名被纳入10天治疗组。两组在年龄或性别分布上无统计学显著差异。10天治疗疗程并不比7天疗程有显著优势（P = 0.78），根除结果不受受试者性别或年龄的影响。两组均未报告不良反应。
采用阿莫西林、克拉霉素和雷贝拉唑联合的三联疗法在根除幽门螺杆菌方面显示出高效性和安全性，且这一结果不受性别或年龄的影响。7天和10天治疗方案之间未观察到差异。
